(PRWEB) March 12, 2014
The “Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)” analyzes and studies the major market drivers, restraints, and opportunities in the U.S., Canada, U.K., France, Germany, Italy, Spain, and Japan.
Browse 50 market data tables and 28 figures spread through 157 pages and in-depth TOC on "Acute Lymphocytic / Lymphoblastic Leukemia Therapeutics Market"
Early buyers will receive 10% customization on reports.
This report studies the acute lymphocytic/lymphoblastic leukemia therapeutics market, with forecast to 2020. The acute market is valued at an estimated $2,777.2 million in 2013 and is expected to reach $3,780.3 million by 2020, at a CAGR of 4.0% from 2015 to 2020.
Inquiry Before Buying: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=518
The acute lymphocytic/lymphoblastic leukemia therapeutics market has experienced stagnant growth in the past few years. The increasing incidence rate of acute lymphocytic/lymphoblastic leukemia and upcoming innovative therapies are the major factors that further propel the growth of this market. However, the high costs of therapies as well as the adverse events associated with therapies are factors that inhibit the growth of the market to a certain extent.
The overall growth of the acute lymphocytic leukemia therapeutics market is largely challenged by the patent expiration of existing drugs. Arranon (nelarabine), a monotherapy drug, lost its patent in February 2013, whereas, Clolar (clofarabine) is due for patent expiration in 2018.
The U.S. has the largest market in 2013 with a market share of approximately 55% to 60% of the acute lymphocytic/lymphoblastic leukemia therapeutics market in G8 countries, followed by Germany and Italy.
Major players in the market include ERYTECH Pharma (France), Talon Therapeutic, Inc. (U.S.), Pfizer, Inc. (U.S.) GlaxoSmithKline plc (U.K.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), and Genzyme Corporation (U.S.).
Browse Related Reports:
Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018
Apheresis Market - (Therapeutic & Donor Apheresis/Automated Blood Component Collection), Applications (Plasmapheresis, Plateletpheresis, RBC/Erythrocytapheresis, Leukapheresis, Photopheresis), Devices & Disposables - Forecasts To 2017
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets